Porton Advanced wins China Class C drug manufacturing license for CGT CDMO work

The NMPA approval allows the company to add commercial contract manufacturing to its cell and gene therapy services after a regulatory inspection of its GMP-compliant China facilities.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.